A recently published study suggests that hydroxychloroquine has a favorable safety profile for women with systemic lupus erythematosus (SLE) during pregnancy and the fetus and should be used continuously during pregnancy. The study retrospectively analyzed disease control and neonatal safety in 24 pregnant patients with SLE treated with hydroxychloroquine between 2006 and 2011. The results showed that 22 of the 24 patients were treated with hydroxychloroquine continuously during pregnancy, and 21 patients had stable SLE without recurrence; 2 patients discontinued hydroxychloroquine after pregnancy and increased the dose of glucocorticoids and added hydroxychloroquine again when SLE activity appeared in the middle of pregnancy, and the SLE was stable until delivery and postpartum; 3 patients were diagnosed with gestational hypertension and 3 patients had preterm delivery; 2 patients added hydroxychloroquine during pregnancy. After the addition of hydroxychloroquine during pregnancy, two patients developed transient anorexia and alopecia respectively, which were not treated specifically and resolved spontaneously after about 3 weeks. None of the patients showed any ocular discomfort or visual field defects. Neonatal hearing screening and height and weight were within normal limits, and no cardiopulmonary abnormalities or growth abnormalities were found.